Researcher Profile Form First National Pediatric Brain Tumor Research Meeting March 9, 2025 - Jerusalem
Researcher: Dr. Tehila Ben Moshe
Current Role & Affiliation
Title/Position: Founder, CEO and chairman Biond Biologics
Institution: Biond Biologics
Email: tehila@biondbio.com
Phone: 052-3319649
Dr. Tehila Ben Moshe is the CEO of Biond Biologics
Research Focus
Biond has developed INspire, an intracellular delivery platform for Biologics. This platform technology delivers various types of protein-based biologics, e.g. antibodies, nanobodies or enzymes, inside cells, allowing to drug intracellular-targets currently considered “undruggable”. Using INspire, we have successfully delivered agents targeting KRAS, BRAF and HPV-E7, overcoming the fundamental challenges of the intracellular delivery of biologics. We have further shown intracellular functionality of all delivered agents.The INspire delivery technology is based on a chemically modified carrier protein which is further chemically conjugated to a biologic payload (antibodies, etc.). The carrier’s modification is characterized by a high and concentrated positive charge that enables cell internalization and efficient endosomal escape, delivering the payloads to the cytoplasm. The positive charges are further transiently masked, neutralizing the positive charges and adding negative charges, to enable clinically relevant PK and biodistribution.
Current Projects Related to Pediatric Brain Tumors
Evaluation of Biond’s technology in brain tumors is currently under evaluation.
Laboratory/Research Resources
Biond’s technology may be included in a collaborative study evaluating it’s use with an innovative anti tumoral therapy
Collaboration Interests
combination of Biond’s technology with an anti tumoral therapy
Keywords
Drug delivery, Protein carrier, Targeted therapy,
Recent Relevant Publications
1. R.Perets. et.al. Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors.Investigational immunotherapy Volume 35, Supplement 2S675 September 2024
2. Mandel I, et.al. T.BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression.J Immunother Cancer. 2022 Sep;10(9):e004859. doi: 10.1136/jitc-2022-004859.
Brief Bio
Dr Tehila Ben Moshe is the founder of Biond Biologis and had served as Biond’s CEO and Board of Directors chairperson since the company’s inception. Prior to founding Biond, She was the CEO of cCAM Biotherapeutics and led the immuno-oncology company from launch through drug discovery and development and early stage clinical trials. The company was subsequently acquired by Merck (MSD) in 2015. Prior to her entrepreneurial career, Tehila led R&D projects at Protalix Biotherapeutics (NYSE/TASE: PLX) driving the development of ‘Bio-Better’ proteins from early stage up to clinic trials. Dr Ben Moshe holds a Ph.D. in Biochemistry from the Weizmann Institute where she studied immune signaling pathways in health and disease. She is the author of multiple patents and peer-reviewed scientific publications.
